JP2021531280A5 - - Google Patents

Info

Publication number
JP2021531280A5
JP2021531280A5 JP2021502704A JP2021502704A JP2021531280A5 JP 2021531280 A5 JP2021531280 A5 JP 2021531280A5 JP 2021502704 A JP2021502704 A JP 2021502704A JP 2021502704 A JP2021502704 A JP 2021502704A JP 2021531280 A5 JP2021531280 A5 JP 2021531280A5
Authority
JP
Japan
Prior art keywords
protein
marker
disease
glial cell
manipulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021502704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531280A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023395 external-priority patent/WO2019190879A1/en
Publication of JP2021531280A publication Critical patent/JP2021531280A/ja
Publication of JP2021531280A5 publication Critical patent/JP2021531280A5/ja
Priority to JP2024063938A priority Critical patent/JP7697096B2/ja
Priority to JP2025097962A priority patent/JP2025123315A/ja
Pending legal-status Critical Current

Links

JP2021502704A 2018-03-27 2019-03-21 神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療 Pending JP2021531280A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024063938A JP7697096B2 (ja) 2018-03-27 2024-04-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療
JP2025097962A JP2025123315A (ja) 2018-03-27 2025-06-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648684P 2018-03-27 2018-03-27
US62/648,684 2018-03-27
PCT/US2019/023395 WO2019190879A1 (en) 2018-03-27 2019-03-21 Car-treg-based therapies for treating neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024063938A Division JP7697096B2 (ja) 2018-03-27 2024-04-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療

Publications (2)

Publication Number Publication Date
JP2021531280A JP2021531280A (ja) 2021-11-18
JP2021531280A5 true JP2021531280A5 (https=) 2022-03-24

Family

ID=68060734

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021502704A Pending JP2021531280A (ja) 2018-03-27 2019-03-21 神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療
JP2024063938A Active JP7697096B2 (ja) 2018-03-27 2024-04-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療
JP2025097962A Pending JP2025123315A (ja) 2018-03-27 2025-06-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024063938A Active JP7697096B2 (ja) 2018-03-27 2024-04-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療
JP2025097962A Pending JP2025123315A (ja) 2018-03-27 2025-06-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療

Country Status (7)

Country Link
US (2) US12173030B2 (https=)
EP (1) EP3773629A4 (https=)
JP (3) JP2021531280A (https=)
KR (2) KR20250174989A (https=)
CN (1) CN112867496B (https=)
AU (1) AU2019242381B2 (https=)
WO (1) WO2019190879A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773629A4 (en) 2018-03-27 2022-01-19 AZTherapies, Inc. CAR-TREG-BASED THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CN116134144A (zh) 2020-04-23 2023-05-16 Az治疗股份有限公司 细胞的hla-i类mhc消融
EP4157877A2 (en) * 2020-05-28 2023-04-05 AZTherapies, Inc. Car-treg-based therapies targeting myelin oligodendrocyte glycoprotein (mog) for treating neurodegenerative diseases
EP4396216A1 (en) * 2021-09-03 2024-07-10 Sangamo Therapeutics, Inc. Mog-binding proteins and uses thereof
TW202321286A (zh) * 2021-09-21 2023-06-01 英商圭爾醫療有限公司 抗p75ntr嵌合抗原受體
GB202113674D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
GB202113673D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
CN118272314A (zh) * 2024-04-15 2024-07-02 华中科技大学同济医学院附属同济医院 一种具有良好血脑屏障通透性的car-t细胞、产品及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140971A2 (en) * 2006-06-06 2007-12-13 F. Hoffmann-La Roche Ag Cell adhesion proteins as biomarker for alzheimer's disease
US20080027001A1 (en) * 2006-07-07 2008-01-31 Andrew Wood Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
EP2673300B1 (en) * 2011-02-11 2016-08-24 Memorial Sloan-Kettering Cancer Center Hla-restricted, peptide-specific antigen binding proteins
US20140348808A1 (en) * 2011-05-19 2014-11-27 Olga De La Rosa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
SG11201705401YA (en) * 2014-12-30 2017-08-30 The Brigham And Women`S Hospital Inc Methods to improve cell therapy
WO2016161372A1 (en) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
SI3280441T1 (sl) * 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
JP7123794B2 (ja) 2015-12-09 2022-08-23 メモリアル スローン ケタリング キャンサー センター 免疫細胞組成物及びそれを使用する方法
KR102585074B1 (ko) * 2017-11-11 2023-10-04 마이크로머티어리얼즈 엘엘씨 고압 프로세싱 챔버를 위한 가스 전달 시스템
EP3773629A4 (en) 2018-03-27 2022-01-19 AZTherapies, Inc. CAR-TREG-BASED THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP4157877A2 (en) * 2020-05-28 2023-04-05 AZTherapies, Inc. Car-treg-based therapies targeting myelin oligodendrocyte glycoprotein (mog) for treating neurodegenerative diseases

Similar Documents

Publication Publication Date Title
JP2021531280A5 (https=)
US12296025B2 (en) AAV capsid variants and uses thereof
Ford et al. Human pluripotent stem cells-based therapies for neurodegenerative diseases: current status and challenges
Huebner et al. Axon regeneration in the peripheral and central nervous systems
Huang et al. Engineered basic fibroblast growth factor-overexpressing human umbilical cord-derived mesenchymal stem cells improve the proliferation and neuronal differentiation of endogenous neural stem cells and functional recovery of spinal cord injury by activating the PI3K-Akt-GSK-3β signaling pathway
Dantuma et al. Stem cells for the treatment of neurodegenerative diseases
MD3672614T2 (ro) Vezicule extracelulare modificate și utilizări ale acestora
MA33609B1 (fr) Molecules de liaison a dll4
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
JP2022524338A5 (https=)
JP2017502920A5 (https=)
JP2014520148A (ja) 治療のための神経筋接合部への標的化
CN111315779A (zh) 抗-cd3抗体及包含其的用于癌症治疗的药物组合物
JP2022512749A (ja) Ｌｒｉｇ－１タンパク質に特異的な結合分子及びその用途
MA35233B1 (fr) Molecules de liaison bispecifiques se liant à dii4 et ang2
JP2020072685A (ja) クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体
Gozes et al. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide)
KR20210038841A (ko) 게놈 편집을 위한 방법 및 조성물
US20180111991A1 (en) Modulators of activin and methods for modulating immune responses and t follicular helper cells
CN121488045A (zh) Aav衣壳变体及其用途
CA3110309A1 (en) Treating spinal cord injury (sci) and brain injury using gsx1
JP2021534206A5 (https=)
JP2023531378A5 (https=)
WO2011057144A2 (en) Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
Tuinstra et al. Gene delivery to overcome astrocyte inhibition of axonal growth: An in vitro Model of the glial scar